CareDx Inc CDNA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
CareDx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
CareDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
CareDx Appoints Keith Kennedy Chief Operating Officer and Jessica Meng Chief Commercial Officer
-
CareDx Announces Transplant Community Secures Win Reaffirming Longstanding Medicare Coverage for AlloSure and AlloMap Testing
-
CareDx Reports Second Quarter 2024 Results and Increases Revenue Guidance
-
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of CareDx, Inc. (NASDAQ: CDNA)
-
CareDx to Report Second Quarter 2024 Financial Results
Trading Information
- Previous Close Price
- $29.81
- Day Range
- $29.50–30.32
- 52-Week Range
- $4.80–34.84
- Bid/Ask
- $29.69 / $30.30
- Market Cap
- $1.57 Bil
- Volume/Avg
- 443,000 / 880,439
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 5.28
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- 1.74%
Company Profile
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre-and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company’s commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates major revenue from the Testing services.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Stock Style Box
- Small Growth
- Total Number of Employees
- 643
- Website
- https://www.caredx.com
Comparables
Valuation
|
Metric
|
CDNA
|
VCYT
|
CSTL
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 75.82 | 232.91 |
Price/Book Value | 5.90 | 2.29 | 1.82 |
Price/Sales | 5.28 | 6.32 | 2.69 |
Price/Cash Flow | — | 37.42 | 14.64 |
Price/Earnings
CDNA
VCYT
CSTL
Financial Strength
|
Metric
|
CDNA
|
VCYT
|
CSTL
|
|---|---|---|---|
Quick Ratio | 3.77 | 3.96 | 7.75 |
Current Ratio | 4.09 | 4.44 | 8.12 |
Interest Coverage | — | −13,015.40 | −54.71 |
Quick Ratio
CDNA
VCYT
CSTL
Profitability
|
Metric
|
CDNA
|
VCYT
|
CSTL
|
|---|---|---|---|
Return on Assets (Normalized) | −1.39% | 9.55% | 7.97% |
Return on Equity (Normalized) | −2.11% | 10.25% | 9.08% |
Return on Invested Capital (Normalized) | −4.62% | 9.19% | 6.49% |
Return on Assets
CDNA
VCYT
CSTL
Diagnostics & Research Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Thermo Fisher Scientific Inc
TMO
| Rjdphxtkjp | Ngf | $234.7 Bil | |||
| Danaher Corp
DHR
| Qpnzqtzrn | Fvgbxsj | $198.9 Bil | |||
| IQVIA Holdings Inc
IQV
| Jcsbxcmy | Vcrrnlg | $42.8 Bil | |||
| Agilent Technologies Inc
A
| Klkxztmsqr | Tlcd | $42.5 Bil | |||
| IDEXX Laboratories Inc
IDXX
| Sxfbpbpfmx | Jrvc | $42.1 Bil | |||
| Mettler-Toledo International Inc
MTD
| Jvyhxhpf | Mtcqmxp | $31.4 Bil | |||
| Icon PLC
ICLR
| Tcwjhkydq | Xkztsp | $23.7 Bil | |||
| Waters Corp
WAT
| Qzkgjbzsxc | Wfjsk | $21.2 Bil | |||
| Illumina Inc
ILMN
| Mjytnpwr | Bnnst | $20.7 Bil | |||
| Labcorp Holdings Inc
LH
| Snvndcypm | Gxttfr | $18.6 Bil |
United States